Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00689910 |
Recruitment Status
:
Withdrawn
First Posted
: June 4, 2008
Last Update Posted
: March 29, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will evaluate the pharmacokinetic disposition of raltegravir in pregnant HIV-1 infected women. These results will be compared to pharmacokinetic data obtained following pregnancy as well as to studies previously carried out in nonpregnant women and male patients. By determining the disposition characteristics for this specific patient population, antiretroviral (ARV) dosing can be optimized during pregnancy. Appropriate dosing is necessary to minimize adverse effects, slow progression of disease, and further reduce the risk for vertical transmission. Data will also be obtained on genital tract penetration and placenta transfer of raltegravir to the newborn.
The subjects enrolled in this study will take an antiretroviral based regimen containing raltegravir twice daily both during and after their pregnancy. The specific regimen will be chosen by their own primary care provider based on their antiretroviral history and resistance testing. They will undergo a series of blood sampling for pharmacokinetic analysis over 12 hours on two occasions; a) during their 3rd trimester and b) approximately 3 months postpartum. Concentrations of raltegravir in the infant will be assessed by cord and infant blood sample at delivery and a blood sample at approximately 3 months of age.
Hypothesis: The pharmacokinetic exposure of raltegravir as measured by the 12 hour area under the plasma concentration versus time curve (AUC0-12h) during third trimester pregnancy is similar to the AUC0-12h estimated three months post-partum.
Condition or disease |
---|
HIV Infections |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum |
Study Start Date : | February 2008 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Female, 16 years old or older
- Pregnant, at least 14 weeks gestation in order to initiate raltegravir treatment if decided by their pregnancy health care provider. The first pharmacokinetic study visit occurs no sooner than 26 weeks gestation (3rd trimester)
- Normal fetal heart motion by ultrasound, vital signs and brief physical exam as conducted by their primary pregnancy health care provider within two weeks of study entry (part of their standard prenatal care)
- Intolerance or resistance to at least two classes of antiretroviral agents
- Availability of a raltegravir-optimized background regimen based on referring provider's selection and resistance testing
- English or Spanish speaking
Exclusion Criteria:
- Inability to follow study protocol or drug administration
- Women who are planning to breastfeed (this is not recommended for HIV-infected women to reduce HIV transmission to the baby)
- Women unable to sign informed consent
- Women with a history of anaphylaxis or other life threatening adverse event associated with antiretroviral therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00689910
United States, California | |
East Bay AIDS Center | |
Oakland, California, United States, 94609 | |
UC Davis | |
Sacramento, California, United States, 95817 | |
San Francisco General Hospital | |
San Francisco, California, United States, 94110 | |
UC San Francisco | |
San Francisco, California, United States, 94110 |
Responsible Party: | Francesca Aweeka, University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00689910 History of Changes |
Other Study ID Numbers: |
PK of Ral in Pregnant Women |
First Posted: | June 4, 2008 Key Record Dates |
Last Update Posted: | March 29, 2012 |
Last Verified: | March 2012 |
Keywords provided by University of California, San Francisco:
pharmacokinetics pregnancy Raltegravir |
HIV antiretroviral Treatment of HIV in pregnant women with Raltegravir |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Raltegravir Potassium Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents HIV Integrase Inhibitors Integrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |